The U.S. Food and Drug Administration on Friday gave the green light to GSK’s respiratory syncytial virus vaccine for high-risk adults aged 50 to 59, opening the door for more people in this age group to protect themselves against the virus
MedPage Today) — In a groundbreaking move, the FDA has given the green light to the first-ever mRNA-1345 vaccine (mRESVIA) designed to combat respiratory syncytial virus (RSV) in adults aged 60 and older. This exciting development aims to shield seniors from serious lower respiratory tract disease, Moderna revealed Friday in an official press release
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More